Puma Biotechnology Crecimiento futuro
Future controles de criterios 0/6
Se prevé que los ingresos y los beneficios de Puma Biotechnology disminuyan a un ritmo anual de 4.1% y 45.4% respectivamente, mientras que se espera que el BPA disminuya un 43.8% por año.
Información clave
-45.4%
Tasa de crecimiento de los beneficios
-43.8%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 28.3% |
| Tasa de crecimiento de los ingresos | -4.1% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 20 Nov 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest
Nov 14
Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?
Sep 07Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop
Aug 15The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%
Jun 07Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today
Jun 05We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings
May 09Puma Biotechnology: A Story In Flux Heading Into Mid-2024
May 05Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?
Apr 10There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump
Mar 01Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden
Dec 27Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet
Sep 08Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%
Apr 17We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt
Dec 14Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib
Sep 20Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt
Sep 05Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2026 | 227 | 20 | 50 | 60 | 2 |
| 12/31/2025 | 221 | 20 | 58 | 46 | 2 |
| 12/31/2024 | 224 | 15 | 51 | 39 | 2 |
| 9/30/2024 | 244 | 23 | 34 | 34 | N/A |
| 6/30/2024 | 219 | 9 | 33 | 33 | N/A |
| 3/31/2024 | 227 | 15 | 35 | 36 | N/A |
| 12/31/2023 | 236 | 22 | 14 | 27 | N/A |
| 9/30/2023 | 229 | 4 | 5 | 24 | N/A |
| 6/30/2023 | 230 | -2 | 11 | 31 | N/A |
| 3/31/2023 | 235 | 5 | -6 | 14 | N/A |
| 12/31/2022 | 228 | 0 | -23 | -16 | N/A |
| 9/30/2022 | 218 | 10 | -29 | -29 | N/A |
| 6/30/2022 | 207 | -34 | -36 | -36 | N/A |
| 3/31/2022 | 201 | -49 | -22 | -22 | N/A |
| 12/31/2021 | 253 | -29 | 21 | 21 | N/A |
| 9/30/2021 | 250 | -48 | 20 | 20 | N/A |
| 6/30/2021 | 255 | -35 | 12 | 12 | N/A |
| 3/31/2021 | 272 | -27 | 18 | 28 | N/A |
| 12/31/2020 | 225 | -60 | -9 | 1 | N/A |
| 9/30/2020 | 235 | -56 | -2 | 8 | N/A |
| 6/30/2020 | 241 | -42 | -11 | -1 | N/A |
| 3/31/2020 | 224 | -82 | 27 | 27 | N/A |
| 12/31/2019 | 272 | -76 | 22 | 22 | N/A |
| 9/30/2019 | 280 | -95 | 28 | 28 | N/A |
| 6/30/2019 | 287 | -92 | 28 | 28 | N/A |
| 3/31/2019 | 284 | -99 | -35 | -34 | N/A |
| 12/31/2018 | 251 | -114 | -25 | -24 | N/A |
| 9/30/2018 | 202 | -147 | -117 | -67 | N/A |
| 6/30/2018 | 145 | -210 | N/A | -114 | N/A |
| 3/31/2018 | 94 | -243 | N/A | -143 | N/A |
| 12/31/2017 | 28 | -292 | N/A | -172 | N/A |
| 9/30/2017 | 6 | -301 | N/A | -178 | N/A |
| 6/30/2017 | N/A | -289 | N/A | -158 | N/A |
| 3/31/2017 | N/A | -278 | N/A | -143 | N/A |
| 12/31/2016 | N/A | -276 | N/A | -142 | N/A |
| 9/30/2016 | N/A | -265 | N/A | -134 | N/A |
| 6/30/2016 | N/A | -260 | N/A | -136 | N/A |
| 3/31/2016 | N/A | -258 | N/A | -139 | N/A |
| 12/31/2015 | N/A | -239 | N/A | -154 | N/A |
| 9/30/2015 | N/A | -225 | N/A | -140 | N/A |
| 6/30/2015 | N/A | -200 | N/A | -127 | N/A |
| 3/31/2015 | N/A | -175 | N/A | -110 | N/A |
| 12/31/2014 | N/A | -142 | N/A | -77 | N/A |
| 9/30/2014 | N/A | -110 | N/A | -72 | N/A |
| 6/30/2014 | N/A | -89 | N/A | -60 | N/A |
| 3/31/2014 | N/A | -63 | N/A | -54 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que los beneficios de PBYI disminuyan en los próximos 3 años (-45.4% al año).
Beneficios vs. Mercado: Se prevé que los beneficios de PBYI disminuyan en los próximos 3 años (-45.4% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de PBYI disminuyan en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos de PBYI disminuyan en los próximos 3 años (-4.1% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos de PBYI disminuyan en los próximos 3 años (-4.1% al año).
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de PBYI se prevé que sea elevada dentro de 3 años.